THE EFFECT OF +GX ACCELERATION ON PLATELET ACTIVATION AS DETERMINED BY PL. (U) AIR FORCE AEROSPACE MEDICAL RESEARCH LAB WRIGHT-PATTERSON AFB. F S CRAMER ET AL.

UNCLASSIFIED APR 85 AFAMRL-TR-85-038 F/G 6/19 NL
THE EFFECT OF +Gx ACCELERATION ON PLATELET ACTIVATION AS DETERMINED BY PLASMA PLATELET FACTOR 4 LEVELS

T. J. JENNINGS, CAPT, USAF, MC, FS
C. T. OLSON, LT COL, USAF, BSC
G. A. McDONALD, SSGT, USAF
L. L. HOWELL, SSGT, USAF
J. R. DAVIS M.D.

DEPARTMENT OF AEROSPACE MEDICINE
WRIGHT STATE UNIVERSITY, DAYTON OH.

F. S. CRAMER, COL, USAF, MC, FS

HYPERBARIC MEDICINE DIVISION
USAF SCHOOL OF AEROSPACE MEDICINE,
BROOKS AFB, TX

APRIL 1985

Approved for public release; distribution unlimited.
NOTICES

When US Government drawings, specifications, or other data are used for any purpose other than a definitely related Government procurement operation, the Government thereby incurs no responsibility nor any obligation whatsoever, and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data, is not to be regarded by implication or otherwise, as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use, or sell any patented invention that may in any way be related thereto.

Please do not request copies of this report from Air Force Aerospace Medical Research Laboratory. Additional copies may be purchased from:

National Technical Information Service
5285 Port Royal Road
Springfield, Virginia 22161

Federal Government agencies and their contractors registered with Defense Technical Information Center should direct requests for copies of this report to:

Defense Technical Information Center
Cameron Station
Alexandria, Virginia 22314

TECHNICAL REVIEW AND APPROVAL
AFAMRL-TR-85-038

The voluntary informed consent of the subjects used in this research was obtained as required by Air Force Regulation 169-3.

This report has been reviewed by the Office of Public Affairs (PA) and is releasable to the National Technical Information Service (NTIS). At NTIS, it will be available to the general public, including foreign nations.

This technical report has been reviewed and is approved for publication.

FOR THE COMMANDER

HENNING E. VON GIERKE, Dr Ing
Director
Biodynamics and Bioengineering Division
Air Force Aerospace Medical Research Laboratory
The Effect of +Gx Acceleration on Platelet Activation as Determined

Six healthy men were exposed to a +Gx acceleration (chest to back) profile with peak +Gx levels of 5, 8, and 9 G. Platelet factor 4 levels and platelet counts were measured prior to and immediately following the acceleration exposure. The +Gx acceleration exposure did not affect either parameter, however elevated pre-acceleration platelet factor 4 levels were found in five of six subjects. The possible significance of this is discussed.
TABLE OF CONTENTS

SECTION                  PAGE
INTRODUCTION             3
METHODS                  4
Centrifuge               4
Subjects                 4
Data Collection          5
Platelet Factor 4 assay  5
Statistical Analysis     5
RESULTS                  6
DISCUSSION               6
ACKNOWLEDGEMENT          8
REFERENCES               9

FIGURE LEGEND

Figure 1
+Gx Acceleration Profile

LIST OF TABLES

TABLE                  PAGE
1  Subject's Blood Pressures and Heart Rate 11
2  Subject's Platelet Factor 4 Concentration and Platelet Counts 12
INTRODUCTION

Future space missions will expose man to unique combinations of environmental stresses. Decompression and +Gx acceleration exposure is one such combination. It is important to determine if there are some features of these stresses which by themselves are benign, but in combination can result in problems for the astronaut.

Evidence exists implicating platelets and platelet activation as a factor in the pathogenesis of decompression sickness. Light and electron microscopic studies show platelets adhering and aggregating to a protein matrix that surrounds the intravascular bubbles (7, 10). Rats with thrombocytosis have a higher incidence of decompression sickness than control rats (2). Platelet counts are shown to decrease with decompression sickness (2, 5), suggesting that platelets are being consumed during decompression. Finally, when rats are exposed to explosive decompression and given infusions of adenosine diphosphate (ADP), a stimulant of platelet aggregation, the interval between the decompression and the occurrence of hypotension and death is shortened (11).

Recently several groups have reported that platelets are activated in normal, healthy subjects following exercise (9, 14, 15). One method used to quantify platelet activation is to determine platelet factor 4 serum concentrations (13).

+Gx acceleration (chest to back) provides a significant physical stress in man. At acceleration levels greater than +4 Gx, the subject experiences chest pain. Breathing becomes difficult, causing the subject to become dyspneic and to breathe using his abdominal muscles. Above +6Gx, pulmonary volumes are reduced, and the subject is unable to move his arms and legs (4, 3).
The purpose of this study was to determine whether +Gx acceleration, using an acceleration profile proposed for future space launches, causes platelet activation as determined by platelet factor 4 concentrations.

METHODS

Centrifuge

The experiment was conducted on the Dynamic Environment Simulator (DES), a 3 axis, 19 foot radius, man-rated centrifuge located at the Air Force Aerospace Medical Research Laboratory, Wright-Patterson AFB, Ohio. The acceleration profile consisted of 3 +Gx peaks of 5, 8, and 9 g over five minutes (figure 1).

Subjects

Six healthy, active duty Air Force men, ranging from twenty-four to thirty-six years of age, were used in the experiment. Four subjects were members of the centrifuge human subject panel and had passed a rigorous qualifying medical examination consisting of a history, physical, and laboratory examinations including EKG and stress EKG. Two months following the experiment, one subject was found to have adult onset diabetes, requiring 20 units NPH insulin for control. He had no sign of micro- or macrovascular disease at the time of diagnosis. Two subjects were aircrew members and did not have a stress EKG as part of their initial examination. Four subjects had less than five rides on the centrifuge, and four subjects had had no previous exposures to +Gx acceleration.

All subjects were briefed concerning the hazards of the experiment and signed consent forms. Specifically the subjects were told that: they would have difficulty breathing, they might develop petechiae, become motion sick, or develop a cardiac arrhythmia during the acceleration exposure. The subjects did not take any medication known to interfere
with platelet function for at least two weeks prior to the experiment. One subject was taking minocycline for acne.

Data Collection

Blood pressure was measured and venous blood samples were collected prior to and following (within 2-3 minutes) the acceleration exposure. An EKG rhythm strip was recorded prior to, during, and following the acceleration exposure. When it was found that the pre-acceleration platelet factor 4 blood levels were elevated, blood was collected on the subjects at rest. Due to scheduling difficulties, only four subjects had a resting blood sample drawn.

Platelet Factor 4 assay

Blood was collected from the subjects through a 20 gauge needle by a clean venipuncture in a single attempt. Blood was first collected in an EDTA tube and used for a platelet count determination using a Coulter model 5 plus electronic cell counter. This counter measures platelets accurate to ± 1 X 10³ cells/mm³. The second blood sample was collected in a Thrombotect R tube (Abbott Laboratories, North Chicago, IL.). The tube was immediately inverted, then rapidly placed in an ice bath. After 30 minutes in the ice bath, the tube was centrifuged at 2500 G for 20 minutes, after which the plasma was transferred to another tube and frozen at -20° C for up to six weeks prior to analysis.

Platelet factor 4 (PF₄) levels were determined by radioimmunoassay using a commercial kit (Abbott Laboratories, North Chicago, IL.) with a reported normal range of 0 to 10.4 ng/ml. PF₄ levels were determined in duplicate.

Statistical Analysis

In analyzing the change from pre- to post acceleration, problems with lack of normality occurred. Instead of performing t-tests on suitable
transformations of the data, the Wilcoxon signed rank test was used. In all cases, the null hypothesis $H_0: \Delta = 0$ was tested against the alternative hypothesis $H_a: \Delta \neq 0$. With only 6 subjects, it is difficult to make substantial conclusions. However, with the Wilcoxon test, all 6 subjects would have to change in the same direction to achieve significance ($p < 0.05$).

RESULTS

Table 1 shows the maximum heart rates and blood pressures for the subjects. No significant changes were found between the pre- and post acceleration blood pressures and heart rates (Table 1). The mean subject heart rate during the acceleration exposure increased by 28 beats per minute. This increase was significant ($p=0.031$).

Platelet factor 4 levels and platelet counts did not change following the $+G_x$ acceleration (Table 2). Five of six subjects had elevated pre-acceleration $\text{PF}_4$ concentrations if compared to reported normal levels of $0-12$. Three subjects, who had elevated pre-acceleration $\text{PF}_4$ levels, had either normal baseline controls or a baseline control dramatically lower than the pre-acceleration level. Subject 4 was the subject who developed adult onset diabetes. His $\text{PF}_4$ levels were similar to the mean values, and no change in his platelet factor 4 level was found following the acceleration exposure.

DISCUSSION

The subjects' platelet counts did not change following the acceleration exposure. Previous studies have found that following strenuous exercise, the platelet count becomes elevated (4,12). This fact and the finding that the mean peak heart rate during the $+G_x$ acceleration was only 99, suggests that the $+G_x$ acceleration profile was not as physically stressful as anticipated. Another study performed in our laboratory, using
the same acceleration profile, found the maximum heart rate to be 102 and
the maximum respiratory rate 35. +Gx acceleration is significantly
stressful to the pulmonary system, but only mildly stressful to the
cardiovascular system.

Platelet factor 4 plasma concentrations were not increased following
the acceleration exposure which suggests that the proposed +Gx acceleration
does not activate platelets. Another possible explanation is that
pre-acceleration platelet factor 4 elevation masked any increase in
platelet factor 4 activity resulting from the +Gx acceleration. Since the
maximum concentration the assay was capable of measuring was 100 ng/ml,
well above the platelet factor 4 levels measured in this study, this second
possibility seems less likely.

+Gx acceleration may enhance the effect of decompression by other
mechanisms. For example, +Gx acceleration compresses the astronaut's
tissues. This compression may increase the release of gas bubbles from the
tissues, thereby providing some micronuclei which can grow rapidly under
hypobaric conditions.

Five of six subjects had elevated platelet factor 4 levels prior to
the acceleration. This finding was unexpected. Resting baseline values
were found to be normal or nearly normal for four subjects who had elevated
pre-acceleration platelet factor 4 levels. In addition, there is no reason
to believe that the other two healthy subjects would have elevated resting
baselines. Several explanations are possible. Laboratory error is one
possibility. Difficulties with the platelet factor 4 assay have been
reported (8). However, similar determinations were made using identical
samples on two occasions by different technicians.
Another possible explanation is that subject anxiety may have caused platelet activation. Five of the six participants were inexperienced centrifuge subjects. This +Gx acceleration exposure was the first +Gx acceleration exposure for all the subjects with elevated pre-acceleration platelet factor 4 levels. In addition, all subjects were carefully briefed about what to expect, i.e., chest pressure, difficulty breathing, etc. All these factors would undoubtedly contribute to pre-run anxiety and possibly elevate catecholamine levels. Epinephrine is a well known, potent platelet activator (17). The only subject who had normal pre-acceleration platelet factor 4 levels had had two prior exposures to this +Gx acceleration profile. Unfortunately, attempts to measure plasma epinephrine and norepinephrine levels from the remaining serum were unsuccessful. The finding that anxiety may cause platelet activation has profound implications in the genesis and treatment of decompression and myocardial infarction.

Subject 4, the adult onset diabetic, had platelet factor 4 levels similar to the other subjects. Others have found that the majority of diabetics have normal levels of platelet factor 4 (16) or platelet factor 4-like activity (6).

In summary, the platelet count or platelet factor 4 levels did not change in subjects following +Gx acceleration. Elevated pre-acceleration platelet factor 4 levels were found and might be due to subject anxiety.

ACKNOWLEDGEMENT

The authors would like to thank SSgt Barry Hancock for his technical assistance.
REFERENCES


TABLE 1. Subject's Blood Pressures and Heart Rates

(Prior to, During and Following $+ G(x)$ Acceleration)

<table>
<thead>
<tr>
<th>Subj No.</th>
<th>pre-Gx BP Systolic(mmHg)</th>
<th>post Gx BP Systolic(mmHg)</th>
<th>pre-Gx BP Diastolic(mmHg)</th>
<th>post Gx BP Diastolic(mmHg)</th>
<th>Heart Rate(beats per min.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>128</td>
<td>134</td>
<td>80</td>
<td>84</td>
<td>66</td>
</tr>
<tr>
<td>2</td>
<td>108</td>
<td>118</td>
<td>70</td>
<td>72</td>
<td>65</td>
</tr>
<tr>
<td>3</td>
<td>142</td>
<td>150</td>
<td>88</td>
<td>92</td>
<td>106</td>
</tr>
<tr>
<td>4</td>
<td>128</td>
<td>122</td>
<td>66</td>
<td>74</td>
<td>50</td>
</tr>
<tr>
<td>5</td>
<td>122</td>
<td>126</td>
<td>74</td>
<td>70</td>
<td>95</td>
</tr>
<tr>
<td>6</td>
<td>120</td>
<td>136</td>
<td>82</td>
<td>80</td>
<td>44</td>
</tr>
</tbody>
</table>

**means ±S.E.**

125±11 131±12 77±8 79±8 71±25 99±16* 70±23

*p=.032 when compared to pre- or post
Table 2. Subject's Platelet Factor 4 Concentration and Platelet Counts
(Prior to and Following +G(x) Acceleration)

<table>
<thead>
<tr>
<th>Subj No.</th>
<th>Platelet Factor 4 (ng/ml)</th>
<th>Resting Baseline</th>
<th>pre-Gx</th>
<th>post Gx</th>
<th>Platelet Counts (X10^3/mm)</th>
<th>Resting Baseline</th>
<th>pre-Gx</th>
<th>post Gx</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>17</td>
<td>16</td>
<td>-227</td>
<td>209</td>
<td></td>
<td>-</td>
<td>227</td>
<td>209</td>
</tr>
<tr>
<td>2</td>
<td>10</td>
<td>7</td>
<td>-9</td>
<td>145</td>
<td>158</td>
<td>149</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>-</td>
<td>33</td>
<td>36</td>
<td>-</td>
<td>293</td>
<td>276</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>18</td>
<td>58</td>
<td>63</td>
<td>197</td>
<td>201</td>
<td>185</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>7</td>
<td>34</td>
<td>33</td>
<td>168</td>
<td>176</td>
<td>182</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>5</td>
<td>63</td>
<td>45</td>
<td>186</td>
<td>225</td>
<td>223</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

means ±S.E. 35±22 34±20 213±47 204±43